Thalomid

Stomatitis, Aphthous, severe Erythema nodosum leprosum, Disease + 9 more
Treatment
6 FDA approvals
20 Active Studies for Thalomid

What is Thalomid

ThalidomideThe Generic name of this drug
Treatment SummaryThalidomide is a drug used to treat certain immunological and inflammatory disorders. It works by suppressing the immune system and blocking the growth of new blood vessels in tumors. It also stops the release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. The drug was originally used as a non-barbiturate hypnotic, but was removed from the market due to its teratogenic effects. It has since been reintroduced with additional safety precautions in place.
Thalomidis the brand name
image of different drug pills on a surface
Thalomid Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Thalomid
Thalidomide
2003
4

Approved as Treatment by the FDA

Thalidomide, also known as Thalomid, is approved by the FDA for 6 uses including moderate Erythema nodosum leprosum and severe Erythema nodosum leprosum .
moderate Erythema nodosum leprosum
severe Erythema nodosum leprosum
Multiple Myeloma (MM)
Used to treat Multiple Myeloma (MM) in combination with Dexamethasone
treatment naive multiple myeloma
Used to treat treatment naive multiple myeloma in combination with Melphalan
Multiple Myeloma
Used to treat treatment naive multiple myeloma in combination with Melphalan
Multiple Myeloma
Used to treat Multiple Myeloma (MM) in combination with Dexamethasone

Effectiveness

How Thalomid Affects PatientsThalidomide is a prescription medication originally developed to act as a sedative. It works by altering the levels of certain substances that cause inflammation, such as tumor necrosis factor-alpha (TNF-a), IL-6, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). It is made up of two different isomers, a (+)R and a (−)S, which are both necessary for its effects. When taken alone, only one enantiomer is present, which may lead to its teratogenic (causing birth defects) effects in humans
How Thalomid works in the bodyThalidomide works in a few ways to stop the growth and spread of cancer cells. It binds to a protein that helps to break down two transcription factors which are important for cancer cell survival. It also blocks the production of TNF-alpha, a molecule that helps cancer cells grow, by blocking proteins and RNA related to its production. Finally, it stops the NF-kB and MyD88 pathways, which allow cancer cells to communicate with each other and grow, from working properly. This also gives it an anti-angiogenic effect, meaning it can stop new blood vessels from forming.

When to interrupt dosage

The suggested measure of Thalomid is reliant upon the diagnosed ailment, such as Disease, Uremia and Multiple Myeloma. The amount of dosage can be located in the table beneath, contingent upon the method of delivery (e.g. Tablet, coated - Oral or Capsule).
Condition
Dosage
Administration
Multiple Myeloma
, 200.0 mg, 100.0 mg, 150.0 mg, 50.0 mg
Capsule - Oral, Capsule, , Oral
Stomatitis, Aphthous
, 200.0 mg, 100.0 mg, 150.0 mg, 50.0 mg
Capsule - Oral, Capsule, , Oral
Disease
, 200.0 mg, 100.0 mg, 150.0 mg, 50.0 mg
Capsule - Oral, Capsule, , Oral
Acquired Immunodeficiency Syndrome
, 200.0 mg, 100.0 mg, 150.0 mg, 50.0 mg
Capsule - Oral, Capsule, , Oral
Multiple Myeloma
, 200.0 mg, 100.0 mg, 150.0 mg, 50.0 mg
Capsule - Oral, Capsule, , Oral
Uremia
, 200.0 mg, 100.0 mg, 150.0 mg, 50.0 mg
Capsule - Oral, Capsule, , Oral
Erythema Nodosum Leprosum
, 200.0 mg, 100.0 mg, 150.0 mg, 50.0 mg
Capsule - Oral, Capsule, , Oral
moderate Erythema nodosum leprosum
, 200.0 mg, 100.0 mg, 150.0 mg, 50.0 mg
Capsule - Oral, Capsule, , Oral
Amyloidosis
, 200.0 mg, 100.0 mg, 150.0 mg, 50.0 mg
Capsule - Oral, Capsule, , Oral
Disease
, 200.0 mg, 100.0 mg, 150.0 mg, 50.0 mg
Capsule - Oral, Capsule, , Oral
Waldenstrom Macroglobulinemia
, 200.0 mg, 100.0 mg, 150.0 mg, 50.0 mg
Capsule - Oral, Capsule, , Oral
severe Erythema nodosum leprosum
, 200.0 mg, 100.0 mg, 150.0 mg, 50.0 mg
Capsule - Oral, Capsule, , Oral

Warnings

Thalomid Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Thalidomide may interact with Pulse Frequency
There are 20 known major drug interactions with Thalomid.
Common Thalomid Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Thalidomide is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Thalidomide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Thalidomide is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Thalidomide is combined with Acteoside.
Aldosterone
Major
The risk or severity of adverse effects can be increased when Thalidomide is combined with Aldosterone.
Thalomid Toxicity & Overdose RiskThe toxic dose of thalidomide in rats is 113 mg/kg and 2 g/kg in mice. Studies have found no cancer-causing effects in mice and rats at doses up to 3,000 mg/kg/day and 300 mg/kg/day respectively. Thalidomide also did not cause any mutations or genetic damage in tests. No effects on mating or fertility were seen in rabbits at doses of 100 mg/kg/day for females and 500 mg/kg/day for males. There is no known antidote for an overdose of thalidomide, so supportive care should be given to maintain vital signs
image of a doctor in a lab doing drug, clinical research

Thalomid Novel Uses: Which Conditions Have a Clinical Trial Featuring Thalomid?

43 active trials are being conducted to investigate the potential of Thalomid in ameliorating Primary Amyloidosis, Disease and Uremia.
Condition
Clinical Trials
Trial Phases
Multiple Myeloma
6 Actively Recruiting
Phase 1, Phase 2
moderate Erythema nodosum leprosum
0 Actively Recruiting
Stomatitis, Aphthous
0 Actively Recruiting
severe Erythema nodosum leprosum
0 Actively Recruiting
Disease
8 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Waldenstrom Macroglobulinemia
8 Actively Recruiting
Phase 2, Phase 1
Erythema Nodosum Leprosum
1 Actively Recruiting
Phase 2
Amyloidosis
1 Actively Recruiting
Not Applicable
Disease
0 Actively Recruiting
Uremia
0 Actively Recruiting
Acquired Immunodeficiency Syndrome
4 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Multiple Myeloma
422 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Phase 4, Early Phase 1

Thalomid Reviews: What are patients saying about Thalomid?

5Patient Review
4/28/2010
Thalomid for Repeatedly Occurring Small Ulcers of the Mouth
This is the only thing that has worked for my bechet's syndrom in the ten years I've been searching.
5Patient Review
11/11/2008
Thalomid for Multiple Myeloma
Thalomid put my multiple myeloma into remission, and I couldn't be happier with the results.
5Patient Review
11/16/2008
Thalomid for Multiple Myeloma
I had to up my dosage, but now I'm feeling really good! I'm able to stay active and do the things I love without any problems.
5Patient Review
5/21/2009
Thalomid for Skin Disease in Patients with Discoid Lupus Erythematosus
My skin lessons have cleared up,where nothing else worked. After being on it now for 5 months,I currently have burning of the feet.
4.3Patient Review
8/31/2011
Thalomid for Multiple Myeloma
This medication is doing its job in keeping me in remission, but I have to say that the side effects are pretty tough to deal with. I constantly feel like I have a hangover and I've been on the med for five years now.
3.7Patient Review
8/18/2009
Thalomid for Multiple Myeloma
My feet and ankles began to feel numb and tingly, which then progressed to my fingers. I also started seeing large veins in my feet and legs. Additionally, my legs would occasionally throb. However, I am currently in remission but weak and dizzy.
3.3Patient Review
1/15/2012
Thalomid for Brain Tumor
I've been experiencing some uncomfortable side effects since starting Thalomid, like tingling and numbness in my extremities as well as all-over body jitteriness. I'm going to have an ultrasound soon to see if there are any clots.
2.3Patient Review
11/23/2008
Thalomid for Swollen Itching Skin Lesions and Erosion of Skin
This medicine initially helped with my itchy skin, but then I began to experience bad cramps as a side effect. Additionally, because I have hep C, this medication damaged my liver more and caused me to develop cirrhosis.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about thalomid

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Thalomid prescribed for?

"This medication is used to treat or prevent certain skin conditions such as erythema nodosum leprosum, which is caused by Hansen's disease. Thalidomide is also used to treat a certain type of cancer called multiple myeloma. It works in Hansen's disease by reducing the swelling and redness caused by inflammation."

Answered by AI

Who should not take Thalomid?

"If you are a female and think you may be pregnant, stop taking THALOMID right away and call your doctor right away.

THALOMID may cause severe birth defects or death in unborn babies. If you are pregnant or planning on becoming pregnant, you should not take THALOMID. If you are a female and think you may be pregnant, stop taking THALOMID and call your doctor immediately."

Answered by AI

What was the thalidomide tragedy?

"This paper discusses the evolution of thalidomide as a drug and the potential uses of thalidomide as an anticancer agent.

In the late 1950s and early 1960s, thalidomide was a widely used drug for the treatment of nausea in pregnant women. However, it became apparent in the 1960s that thalidomide treatment resulted in severe birth defects in thousands of children. This paper discusses the evolution of thalidomide as a drug and the potential uses of thalidomide as an anticancer agent."

Answered by AI

What type of drug is Thalomid?

"Thalomid is a medication used to treat the symptoms of bone marrow cancer (Multiple myeloma) and Erythema Nodosum Leprosum (ENL). Thalomid may be used alone or with other medications. Thalomid belongs to a class of drugs called Antineoplastics, Angiogenesis Inhibitor."

Answered by AI

Clinical Trials for Thalomid

Image of Washington University School of Medicine in St Louis, United States.

AI-Generated Question Prompts for Lymphoma and Multiple Myeloma

20 - 99
All Sexes
St Louis, MO
The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments) for patients with hematologic cancers. The intervention will involve tailoring a standardized prompt to patients' individual characteristics and concerns. This prompt will then be used to ask Washington University's (WashU) HIPAA compliant ChatGPT to generate personalized question lists for outpatient appointments. Analyses will assess the impact of personalized QPLs on patients' question-asking behavior; communicative self-efficacy; and self-reported amount and satisfaction with information obtained about their disease and its treatment. Sub-analyses will explore patterns in questions generated by WashU ChatGPT. Patients will also provide feedback pertaining to the perceived helpfulness and ease-of-use of WashU-ChatGPT-generated question lists, as well as their attitudes and intentions regarding use of AI chatbots and whether they would engage in pre-appointment AI-assisted question brainstorming independently in the future.
Waitlist Available
Has No Placebo
Washington University School of MedicineJessica Hahne, MA, MPH
Have you considered Thalomid clinical trials? We made a collection of clinical trials featuring Thalomid, we think they might fit your search criteria.Go to Trials
Image of Washington University School of Medicine in St Louis, United States.

Selinexor for Multiple Myeloma

18+
All Sexes
St Louis, MO
The outcomes in patients with relapsed multiple myeloma refractory to triple-therapy (anti-CD38, immunomodulatory drugs (IMiD) and proteasome inhibitors (PI)) remain poor. These patients are eligible for chimeric antigen receptor T-cells (CAR-T), which rely on redirecting autologous T-cells to clear myeloma cells by targeting B-cell maturation antigen (BCMA). BCMA CAR-T therapy is not curative, and unlike autologous stem cell transplant, there is currently no standard for maintenance therapy post CAR-T which could potentially increase MRD rates and extend progression-free survival. Selinexor is an exportin (XPO1) inhibitor with direct anti-tumor effect used often as an adjunct with other agents as bridging therapy prior to CAR-T. As selinexor does not affect T-cell yields or fitness, T-cell collection on selinexor for CAR-T manufacturing is safe. The aim of this study is to evaluate the safety and toxicity of selinexor in triple-exposed or refractory multiple myeloma patients with high-risk features (adverse risk cytogenetics, less than complete response (CR) post CAR-T, or extramedullary disease) following BCMA CAR-T therapy. The investigators hypothesize that selinexor as maintenance therapy following CAR-T has the potential to act synergistically with CAR-T cells leading to more durable responses.
Phase 1
Waitlist Available
Washington University School of MedicineMark A Schroeder, M.D.Karyopharm Therapeutics Inc
Image of Washington University School of Medicine in St Louis, United States.

NT-I7 + CAR-T Therapy for Multiple Myeloma

18+
All Sexes
St Louis, MO
CAR-T cell therapy is an emerging treatment modality in relapsed and refractory multiple myeloma (MM). CAR-T therapy in MM relies on directing autologous T-cells to detect and clear myeloma cells expressing B-cell Maturation Antigen (BCMA). While BCMA CAR-T cell-treated patients achieve an excellent overall response rate, their response is often not durable. NT-I7 promotes CAR-T cell expansion and efficacy in pre-clinical lymphoma models. In patients receiving CD19-directed CAR-T therapy for lymphoma, NT-I7 augmented CAR-T expansion while being safe and tolerable. The impact of NT-I7 on BCMA CAR-T cells in multiple myeloma is unknown. This is a two-arm, double blind, placebo-controlled, randomized, single-site phase Ib study testing the safety and toxicity of adding NT-I7 to BCMA CAR-T therapy in patients with relapsed and refractory multiple myeloma. The hypothesis is that NT-I7 will promote CAR-T expansion and persistence which will enhance clearance of MM, while maintaining a favorable safety and toxicity profile. Patients receiving standard of care BCMA CAR-T (Cilta-cel) will be randomized to either NT-I7 or placebo. Correlative studies will evaluate CAR-T cell expansion, persistence, immune-phenotype, function and correlate with clinical outcomes.
Phase 1
Waitlist Available
Washington University School of MedicineMichael Slade, M.D., M.S.C.INeoImmuneTech
Have you considered Thalomid clinical trials? We made a collection of clinical trials featuring Thalomid, we think they might fit your search criteria.Go to Trials
Have you considered Thalomid clinical trials? We made a collection of clinical trials featuring Thalomid, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security